Skip to main content

David Charles Montefiori, PhD

Professor of Surgery
Office: Surgical Oncology Res Fac, Durham, NC 27710
Campus Mail: DUMC Box 2926 Med Ctr, Durham, NC 27710

Dr. Montefiori is Professor and Director of the Laboratory for AIDS Vaccine Research and Development in the Department of Surgery, Division of Surgical Sciences, Duke University Medical Center. His major research interests are viral immunology and AIDS vaccine development, with a special emphasis on neutralizing antibodies. One of his highest priorities is to identify immunogens that generate broadly cross-reactive neutralizing antibodies for inclusion in HIV vaccines.  Many aspects of the neutralizing antibody response are studied in his laboratory, including mechanisms of neutralization and escape, epitope diversity among genetic subtypes and geographic origins, ontogeny of broadly neutralizing antibody responses and computationally-assisted vaccine design. Over the years he has explored multiple types of assays for neutralizing antibodies and other potential antiviral antibodies, focusing on assay optimization, standardization, validation and high throughput. The scope of research covers HIV-infected individuals and nonhuman primate models of simian immunodeficiency virus (SIV) and simian-human immunodeficiency virus (SHIV) infection.  Dr. Montefiori also directs a large AIDS vaccine immune monitoring program, which operates in compliance with Good Clinical Laboratory Practice and has served as a national and international resource for standardized assessments of neutralizing antibody responses in preclinical and clinical trials of candidate AIDS vaccines since 1988. In 2002 he chaired the Antibody Laboratory Standardization Working Group that assisted in the design of the Global HIV Vaccine Enterprise Strategic Plan for HIV vaccines. He currently directs the Core Neutralizing Antibody Laboratories for the HIV Vaccine Clinical Trials Network (HVTN), the NIH Preclinical HIV-1 Vaccine Program and the Center for HIV/AIDS Vaccine Immunology- Immunogen Design (CHAVI-ID). He also directs a large Comprehensive Antibody Vaccine Immune Monitoring Consortium (CAVIMC) as part of the Bill and Melinda Gates Foundation's Collaboration for AIDS Vaccine Discovery (CAVD). He has published over 500 original research papers that have helped shape the scientific rationale for antibody-based HIV-1 vaccines.

Education and Training

  • Ph.D., Clemson University, 1982

Publications

Spearman, Paul, Georgia D. Tomaras, David C. Montefiori, Ying Huang, Marnie L. Elizaga, Guido Ferrari, S Munir Alam, et al. “Rapid Boosting of HIV-1 Neutralizing Antibody Responses in Humans Following a Prolonged Immunologic Rest Period.” J Infect Dis 219, no. 11 (May 5, 2019): 1755–65. https://doi.org/10.1093/infdis/jiz008.

Full Text

Pittala, Srivamshi, Kenneth Bagley, Jennifer A. Schwartz, Eric P. Brown, Joshua A. Weiner, Ilia J. Prado, Wenlei Zhang, et al. “Antibody Fab-Fc properties outperform titer in predictive models of SIV vaccine-induced protection.” Mol Syst Biol 15, no. 5 (May 2, 2019): e8747. https://doi.org/10.15252/msb.20188747.

Full Text

Zhou, Mingkui, Michael Humbert, Muhammad M. Mukhtar, Hanna B. Scinto, Hemant K. Vyas, Samir K. Lakhashe, Siddappa N. Byrareddy, et al. “Adaptation of an R5 Simian-Human Immunodeficiency Virus Encoding an HIV Clade A Envelope with or without Ablation of Adaptive Host Immunity: Differential Selection of Viral Mutants.” J Virol 93, no. 9 (May 1, 2019). https://doi.org/10.1128/JVI.02267-18.

Full Text

Pardi, Norbert, Celia C. LaBranche, Guido Ferrari, Derek W. Cain, István Tombácz, Robert J. Parks, Hiromi Muramatsu, et al. “Characterization of HIV-1 Nucleoside-Modified mRNA Vaccines in Rabbits and Rhesus Macaques.” Mol Ther Nucleic Acids 15 (April 15, 2019): 36–47. https://doi.org/10.1016/j.omtn.2019.03.003.

Full Text

Priddy, Frances H., David J. M. Lewis, Huub C. Gelderblom, Hana Hassanin, Claire Streatfield, Celia LaBranche, Jonathan Hare, et al. “Adeno-associated virus vectored immunoprophylaxis to prevent HIV in healthy adults: a phase 1 randomised controlled trial.” Lancet Hiv 6, no. 4 (April 2019): e230–39. https://doi.org/10.1016/S2352-3018(19)30003-7.

Full Text

Magaret, Craig A., David C. Benkeser, Brian D. Williamson, Bhavesh R. Borate, Lindsay N. Carpp, Ivelin S. Georgiev, Ian Setliff, et al. “Prediction of VRC01 neutralization sensitivity by HIV-1 gp160 sequence features.” Plos Comput Biol 15, no. 4 (April 2019): e1006952. https://doi.org/10.1371/journal.pcbi.1006952.

Full Text

Tay, Matthew Zirui, Erika L. Kunz, Aaron Deal, Lu Zhang, Kelly E. Seaton, Wes Rountree, Joshua A. Eudailey, et al. “Rare Detection of Antiviral Functions of Polyclonal IgA Isolated from Plasma and Breast Milk Compartments in Women Chronically Infected with HIV-1.” J Virol 93, no. 7 (April 1, 2019). https://doi.org/10.1128/JVI.02084-18.

Full Text

LaBranche, Celia C., Andrew T. McGuire, Matthew D. Gray, Shay Behrens, Xuejun Chen, Tongqing Zhou, Quentin J. Sattentau, et al. “Correction: HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies.” Plos Pathog 15, no. 3 (March 2019): e1007646. https://doi.org/10.1371/journal.ppat.1007646.

Full Text

Nguyen, Dung N., Bokai Xu, Robyn L. Stanfield, Jennifer K. Bailey, Satoru Horiya, J Sebastian Temme, Deborah R. Leon, et al. “Oligomannose Glycopeptide Conjugates Elicit Antibodies Targeting the Glycan Core Rather than Its Extremities.” Acs Cent Sci 5, no. 2 (February 27, 2019): 237–49. https://doi.org/10.1021/acscentsci.8b00588.

Full Text

Petitdemange, Caroline, Sudhir Pai Kasturi, Pamela A. Kozlowski, Rafiq Nabi, Clare F. Quarnstrom, Pradeep Babu Jagadeesh Reddy, Cynthia A. Derdeyn, et al. “Vaccine induction of antibodies and tissue-resident CD8+ T cells enhances protection against mucosal SHIV-infection in young macaques.” Jci Insight 4, no. 4 (February 21, 2019). https://doi.org/10.1172/jci.insight.126047.

Full Text

Pages